Fulgent Genetics (FLGT) to Release Earnings on Friday

Key Points

• Q1 2026 earnings are scheduled before the open on Friday, May 1; analysts expect EPS of -$0.3854 and revenue of $68.48M, and the company has set FY2026 guidance at -1.45 EPS.
• Although Fulgent beat last quarter's EPS ($0.16 vs. $0.02), it reported a negative net margin (18.75%) and negative ROE, and analysts forecast about -$2 EPS for the current and next fiscal years.
• Shares trade near $16 with a market cap of ~$477M and a consensus price target of $32; ownership is ~48.06% institutional, including recent large purchases such as an $18.5M position by RTW Investments.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Friday, May 1st. Analysts expect Fulgent Genetics to post earnings of ($0.3854) per share and revenue of $68.4830 million for the quarter. Fulgent Genetics has set its FY 2026 guidance at -1.450--1.450 EPS. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 1, 2026 at 8:30 AM ET.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its earnings results on Friday, February 27th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. The firm had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. On average, analysts expect Fulgent Genetics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulgent Genetics Stock Down 1.6%

Shares of NASDAQ:FLGT opened at $16.03 on Friday. Fulgent Genetics has a 52-week low of $13.46 and a 52-week high of $31.04. The company has a 50 day moving average of $17.11 and a two-hundred day moving average of $23.07. The company has a market capitalization of $476.89 million, a price-to-earnings ratio of -8.18 and a beta of 0.89.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on FLGT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fulgent Genetics in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Fulgent Genetics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Finally, Zacks Research downgraded shares of Fulgent Genetics from a "strong-buy" rating to a "hold" rating in a research report on Monday, February 9th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Fulgent Genetics has an average rating of "Hold" and a consensus price target of $32.00.

Hedge Funds Weigh In On Fulgent Genetics

Several institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd boosted its stake in shares of Fulgent Genetics by 33.1% during the 4th quarter. XTX Topco Ltd now owns 22,195 shares of the company's stock valued at $583,000 after buying an additional 5,523 shares during the last quarter. Susquehanna Portfolio Strategies LLC boosted its stake in shares of Fulgent Genetics by 13.4% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 38,480 shares of the company's stock valued at $1,011,000 after buying an additional 4,560 shares during the last quarter. RTW Investments LP purchased a new position in shares of Fulgent Genetics during the 4th quarter valued at approximately $18,521,000. Oxford Asset Management LLP purchased a new position in shares of Fulgent Genetics during the 4th quarter valued at approximately $254,000. Finally, Engineers Gate Manager LP boosted its stake in shares of Fulgent Genetics by 24.1% during the 4th quarter. Engineers Gate Manager LP now owns 16,994 shares of the company's stock valued at $446,000 after buying an additional 3,299 shares during the last quarter. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

About Fulgent Genetics

Fulgent Genetics, Inc NASDAQ: FLGT is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company's infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent's product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.